Blue Ridge Internal Medicine

CLIA Laboratory Citation Details

3
Total Citations
21
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 49D2004750
Address 1922 Thomson Drive - Suite B, Lynchburg, VA, 24501
City Lynchburg
State VA
Zip Code24501
Phone(434) 846-4444

Citation History (3 surveys)

Survey - September 15, 2022

Survey Type: Standard

Survey Event ID: Q89J11

Deficiency Tags: D5403 D5403 D5439 D0000 D5439

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA Recertification survey was conducted at the Blue Ridge Internal Medicine on 09/15/22 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. Specific deficiencies cited are as follows: D5403 PROCEDURE MANUAL CFR(s): 493.1251(b) The procedure manual must include the following when applicable to the test procedure: (1) Requirements for patient preparation; specimen collection, labeling, storage, preservation, transportation, processing, and referral; and criteria for specimen acceptability and rejection as described in 493.1242. (2) Microscopic examination, including the detection of inadequately prepared slides. (3) Step-by-step performance of the procedure, including test calculations and interpretation of results. (4) Preparation of slides, solutions, calibrators, controls, reagents, stains, and other materials used in testing. (5) Calibration and calibration verification procedures. (6) The reportable range for test results for the test system as established or verified in 493.1253. (7) Control procedures. (8)

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 26, 2022

Survey Type: Special

Survey Event ID: FHIU11

Deficiency Tags: D0000 D2016 D2130 D0000 D2016 D2130

Summary:

Summary Statement of Deficiencies D0000 An unannounced CLIA off-site proficiency testing desk review of Blue Ridge Internal Medicine was conducted on 04/26/22 by a Medical Facilities Inspector of the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Regulations. The laboratory was not in compliance with the following Conditions under 42 CFR part 493 CLIA Regulations: D2016 - 42 C.F.R. 493.803 (a)(b)(c) Condition- Successful Participation. D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on the review of the American Association of Bioanalysts (AAB) proficiency testing (PT) scores for the second event in 2021 and the first event in 2022, the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- CASPER 0155D Individual Laboratory Profile report and an interview, the laboratory failed to achieved satisfactory performance of at least 80% for two out of three events for the Red Blood Cell count (RBC) and hematocrit (HCT) analytes, resulting in unsuccessful performance (Refer to D2130). Event Specialty/Analyte Score: 2021 AAB Non-chemistry Event 2 RBC 0%, Hct 0% 2022 AAB Non-chemistry Event 1 RBC 40%, Hct 60% D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on the review of the proficiency testing (PT) scores for the second event in 2021 and the first event in 2022, the CASPER 0155D Individual Laboratory Profile report and an interview, the laboratory failed to achieved satisfactory performance of at least 80% for two out of three events for the Red Blood Cell count (RBC) and hematocrit (HCT) analytes, resulting in unsuccessful performance. Findings include: 1. Off-site PT desk review of the American Association of Bioanalysts (AAB) and the CASPER 0155D Individual Laboratory Profile report revealed the following: Event Specialty/Analyte Score: 2021 AAB Non-chemistry Event 2 RBC 0%, Hct 0% 2022 AAB Non-chemistry Event 1 RBC 40%, Hct 60% The laboratory received unsuccessful AAB PT scores for the above listed analytes. 2. A phone interview with the lab consultant on 04/26/22 at 1345 confirmed the findings. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 27, 2021

Survey Type: Standard

Survey Event ID: H1FM11

Deficiency Tags: D0000 D2016 D2093 D2096 D2127 D0000 D2016 D2093 D2096 D2127

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA Initial on-site survey was conducted at the Blue Ridge Internal Medicine on January 27, 2021 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. The initial contact and entrance interview with laboratory conducted on January 11, 2021 with off-site record review of documentation and a follow-up phone conference on January 22, 2021. Specific deficiencies cited are as follows: The laboratory was not in compliance with the following 42 CFR part 493 CLIA Regulations: D2016 - 42 C.F.R. 493-803 Condition: Successful Participation. The laboratory is performing COVID-19 testing and is in compliance with the applicable COVID-19 reporting requirements. D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- This CONDITION is not met as evidenced by: A. Based on the review of the proficiency testing (PT) scores for all three events in 2020, the review of the CASPER 0155D Individual PT report and an interview with the primary testing personnel, the laboratory failed to achieved satisfactory performance of at least 80% for two consecutive events for the following parameters, resulting in unsuccessful performance (Cross Reference D 2096): 2020 Alanine aminotransferase (ALT) Event 1= 60% Event 2=0% Sodium (NA) Event 2= 0% Event 3= 0% B. Based on the review of the proficiency testing (PT) scores for all three events in 2020, the review of the CASPER 0155D Individual PT report, lack of documentation and an interview with the lab consultant and primary testing personnel, the laboratory failed to submit the PT test results for the Chemistry and Hematology modules within the specified time frame for one (1) of 3 events in 2020. (Cross Reference D2093 and D2127). D2093 ROUTINE CHEMISTRY CFR(s): 493.841(d) Failure to return proficiency testing results to the proficiency testing program within the time frame specified by the program is unsatisfactory performance and results in a score of 0 for the testing event. This STANDARD is not met as evidenced by: Based on the review of the proficiency testing (PT) scores for all three events in 2020, the review of the CASPER 0155D Individual PT report, lack of documentation and an interview with the primary testing personnel, the laboratory failed to submit the PT results for the Chemistry module within the specified time frame for one (1) of 3 events in 2020. Findings include: 1. Review of the American Association of Bioanalysts (AAB) PT scores for the all three events in 2020 revealed a score of 0% and lack of documentation of submission of test results for the Chemistry module second event analytes: Alamine aminotrasferease, albumin, alkaline phosphatase, bicarbonate, bilirubin total, calcium, chloride, cholesterol total, creatinine, glucose, potassium, sodium, protein total, triglycerides, urea nitrogen, uric acid, amylase, creatin kinase total, HDL cholesterol, iron, lipase, thyroid stimulating hormone, thyroxine Free, vitamin D, ferritin, folate, prostate specific Ag, testosterone, triiodothyronine free, and vitamin B12. 2. An interview with the lab consultant and primary testing personnel on January 27, 2021 at approximately 10:00 AM confirmed that there was no documentation of submitted test results for the chemistry module for the second event in 2020. They stated, "Due to the confusion of shipments with COVID, our PT samples were received downstairs. When we realized the PT shipment was downstairs, it was too late to submit results to AAB. We did run the samples and did a self-grade." D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: -- 2 of 3 -- Based on the review of the proficiency testing (PT) scores for all three events in 2020, the review of the CASPER 0155D Individual PT report and an interview with the primary testing personnel, the laboratory failed to achieved satisfactory performance of at least 80% for two consecutive events for the alanine aminotransferase (ALT) and Sodium (NA) parameters, resulting in unsuccessful performance. Findings include: 1. Review of the American Association of Bioanalysts (AAB) PT scores for all three events in the calendar year 2020 revealed the following: ALT- Event 1= 60%; Event 2=0% NA- Event 2= 0%; Event 3= 0% The laboratory received an unsuccessful AAB PT score for the above listed analytes. 2. An interview with the lab consultant and primary testing personnel on January 27, 2021 at approximately 9:45 AM confirmed the findings. D2127 HEMATOLOGY CFR(s): 493.851(d) Failure to return proficiency testing results to the proficiency testing program within the time frame specified by the program is unsatisfactory performance and results in a score of 0 for the testing event. This STANDARD is not met as evidenced by: Based on the review of the proficiency testing (PT) scores for all three events in 2020, the review of the CASPER 0155D Individual PT report, lack of documentation and an interview with the primary testing personnel, the laboratory failed to submit the PT results for the hematology module within the specified time frame for one (1) of 3 events in 2020. Findings include: 1. Review of the American Association of Bioanalysts (AAB) PT scores for the all three events in 2020 revealed a score of 0% and lack of documentation of submission of test results for the Hematology module second event analytes: Cell Identification, Red Blood Cell, White Blood Cell Platelets, Hemoglobin and Hematocrit. 2. An interview with the lab consultant and primary testing personnel on January 27, 2021 at approximately 10:00 AM confirmed that there was no documentation of submitted test results for the Hematology module for the second event in 2020. They stated, "Due to the confusion of shipments with COVID, our PT samples were received downstairs. When we realized the PT shipment was downstairs, it was too late to submit results to AAB. We did run the samples and did a self-grade." -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access